Recent evidence suggests that chemokine CXCL12, the cognate agonist of chemokine receptors CXCR4 and ACKR3, reduces thrombin-mediated impairment of endothelial barrier function. A detailed characterization of the effects of CXCL12 on thrombin-mediated human lung endothelial hyperpermeability is lacking and structure-function correlations are not available. Furthermore, effects of other CXCR4/ACKR3 ligands on lung endothelial barrier function are unknown. Thus, we tested the effects of a panel of CXCR4/ACKR3 ligands (CXCL12, CXCL11, ubiquitin, AMD3100, TC14012) and compared the CXCR4/ACKR3 activities of CXCL12 variants (CXCL12α/β, CXCL12(3–68), CXCL121, CXCL122, CXCL12-S-S4V, CXCL12-R47E, CXCL12-K27A/R41A/R47A) with their effects on human lung endothelial barrier function in permeability assays. CXCL12α-enhanced human primary pulmonary artery endothelial cell (hPPAEC) barrier function, whereas CXCL11, ubiquitin, AMD3100 and TC14012 were ineffective. Pre-treatment of hPPAEC with CXCL12α and ubiquitin reduced thrombin-mediated hyperpermeability. CXCL12α-treatment of hPPAEC after thrombin exposure reduced barrier function impairment by 70% (EC50 0.05–0.5nM), which could be antagonized with AMD3100; ubiquitin (0.03–3μM) was ineffective. In a human lung microvascular endothelial cell line (HULEC5a), CXCL12α and ubiquitin post-treatment attenuated thrombin-induced hyperpermeability to a similar degree. CXCL12(3–68) was inefficient to activate CXCR4 in Presto-Tangoβ-arrestin2 recruitment assays; CXCL12-S-S4V, CXCL12-R47E and CXCL12-K27A/R41A/R47A showed significantly reduced potencies to activate CXCR4. While the potencies of all proteins in ACKR3 Presto-Tango assays were comparable, the efficacy of CXCL12(3–68) to activate ACKR3 was significantly reduced. The potencies to attenuate thrombin-mediated hPPAEC barrier function impairment were: CXCL12α/β, CXCL121, CXCL12-K27A/R41A/R47A > CXCL12-S-S4V, CXCL12-R47E > CXCL122 > CXCL12α > CXCL12(3–68). Our findings indicate that CXCR4 activation attenuates thrombin-induced lung endothelial barrier function impairment and suggest that protective effects of CXCL12 are dictated by its CXCR4 agonist activity and interactions of distinct protein moieties with heparan sulfate on the endothelial surface. These data may...
facilitate development of compounds with improved pharmacological properties to attenuate thrombin-induced vascular leakage in the pulmonary circulation.

**Introduction**

Acute respiratory distress syndrome (ARDS) remains a major contributor to morbidity and mortality in critically ill patients [1–4]. It is generally accepted that mild ARDS and its progression into moderate and severe ARDS is caused by local and systemic coagulation and inflammation, which leads to impaired pulmonary endothelial barrier function, third spacing of fluids into the lung and formation of lung edema, the hallmark of ARDS [5, 6]. Thrombin plays an important role in the pathogenesis of ARDS; in addition to functions of thrombin in the clotting cascade, thrombin fulfills diverse roles in inflammation and is well known to impair endothelial barrier function through activation of the G protein-coupled receptors (GPCR) protease-activated receptors (PARs) [7–9]. All four members of the PAR family (PAR1–4) can be activated by thrombin [8–10]. A large body of evidence suggests that PAR-1 is the major mediator of thrombin signaling in vascular endothelial cells [8, 11–14]. PAR-1 is activated when thrombin cleaves its extracellular N-terminal domain between residues Arg-41 and Ser-42, which unmasks a new N-terminus that serves as a tethered ligand [8]. Drugs that limit impairment of the lung endothelial barrier by thrombin, however, are not available, but desirable for their potential to improve outcomes.

Recently, administration of cognate, non-cognate and synthetic chemokine (C-X-C) motif receptor (CXCR) 4 agonists has been shown to attenuate lung injury in various experimental models and CXCL12 (stromal cell-derived factor-1α), the cognate agonist of CXCR4 and atypical chemokine receptor 3 (ACKR3), has been described to attenuate thrombin-induced impairment of endothelial cell barrier function [15–22]. A more detailed pharmacological characterization of these CXCL12-mediated effects, however, is lacking and the effects of other CXCR4/ACKR3 ligands on lung endothelial cell barrier function are ill defined. Moreover, information on the structural requirements of CXCL12 to attenuate thrombin-mediated lung endothelial barrier disruption and the relationship to its CXCR4/ACKR3 agonist activity is not available. Because such data could guide the development of compounds with improved efficacy to reduce thrombin-mediated vascular leakage, we tested the effects of a panel of CXCR4/ACKR3 ligands on the barrier function of human lung vascular endothelial cells. We also compared CXCR4 and ACKR3 activities with effects on thrombin-induced lung endothelial barrier disruption of the wild-type splice variants CXCL12α and CXCL12β, of N-terminal truncated CXCL12 (3–68), a posttranslational modification that occurs in vivo after cleavage of CXCL12 by CD26/dipeptidyl peptidase 4, and of several engineered CXCL12 variants and mutants. These proteins have previously been reported to possess distinct affinities for CXCR4/ACKR3 and altered pharmacological properties [23–31]. Thus, we hypothesized that CXCR4 agonists antagonize thrombin-mediated impairment of lung endothelial cell barrier function and that the engineered CXCL12 variants and mutants show distinct biological activities.

**Materials and methods**

**Proteins, peptides and reagents**

AMD3100 was purchased from Sigma-Aldrich, CXCL12 and CXCL11 from Protein Foundry, ubiquitin from R&D Systems, TC14012 from Tocris Bioscience and human alpha thrombin from Enzyme Research Laboratories. Recombinant CXCL12 variant proteins were expressed in E. coli, refolded, purified and verified by NMR and high-resolution mass spectrometry as previously described [32].
Cells and cell lines

Human primary pulmonary artery endothelial cells (hPPAEC) (ATCC, PCS-100-022) and the human lung microvascular endothelial cell line HULEC-5a (ATCC, CRL-3244) were cultured in vascular cell basal medium (ATCC, PCS-100-030) with endothelial cell growth kit-VEGF (ATCC, PCS-100-041). The HTLA cell line, a HEK293 cell line stably expressing a tTA-dependent luciferase reporter and a β-arrestin2-TEV fusion gene [33], was generously provided by the laboratory of Dr. Bryan Roth and maintained in high glucose Dulbecco’s Modified’s Eagle’s Medium supplemented with 10% (vol/vol) FBS, 1x non-essential amino acids, 100 U/mL penicillin, 100 μg/mL streptomycin, 50 μg/mL hygromycin B, and 2 μg/mL puromycin. All cells were cultured at 37°C, 5% CO₂ in a humidified atmosphere.

In vitro vascular permeability assays

Permeability assays were obtained from Millipore (ECM642) and performed as per manufacturer’s instructions. In brief, 96-well collagen-coated permeability assay plates were pre-hydrated for 15 min, 5x10⁵ cells were seeded on each well and grown to a confluent monolayer for 48 hours. Fluorescein isothiocyanate (FITC)-dextran (20 μg/mL) was then added on top of the monolayer and the amount of FITC-dextran that permeated through the monolayer was quantified by measuring fluorescence in a Synergy 2 Multi-mode Microplate Reader (BioTek, Winooski, VT) at various time points over a 255 min time period.

Proximity ligation assays (PLA)

PLA were performed as described in detail previously [34–36], utilizing mouse anti-ACKR3 (R&D MAB42273) and goat anti-CXCR4 (Abcam Ab1670). The antibodies have been validated for their receptor target previously [35–37]. PLA signals (λexcitation/emission 598/634 nm)) were identified as red spots under a fluorescence microscope.

Presto-Tango β-arrestin 2 recruitment assay

The PRESTO-Tango (parallel receptorome expression and screening via transcriptional output, with transcriptional activation following arrestin translocation) assay was performed as recently described [33]. The Tango plasmids were a gift from Dr. Bryan Roth (all from Addgene). HTLA cells (2.5x10⁵/well) were seeded in a 6-well plate and transfected with 1.5 μg of the Tango plasmids using Lipofectamine 3000 (ThermoScientific). The following day, transfected HTLA cells (1x10⁵ cells/well) were plated onto Poly-L-Lysine pre-coated 96-well microplates and allowed to attach to the plate surface for at least 4 hours prior to treatment. Proteins used for treatment were prepared in twice the final concentration in culture media, added at a 1:1 vol/vol ratio and incubated overnight at 37°C, 5% CO₂ in a humidified environment. The following morning, media was removed from cell culture plates and replaced with a 100 μL 1:5 mixture of Bright-Glo (Promega) and 1x HBSS, 20 mM HEPES solution. Plates were then incubated at room temperature before measuring luminescence on a Biotek Synergy II plate reader.

SDS-polyacrylamide gel electrophoresis (PAGE)

SDS-PAGE was performed utilizing pre-cast mini-PROTEAN TGX gels (Bio-Rad). Lanes were loaded with 1ug of each protein in 25 μL of Laemmli sample buffer with or without 10% 2-mercaptoethanol (SigmaAldich) after boiling for 5 min.
Data analyses

Data are expressed as mean ± SEM from n independent experiments that were performed on different days. Data were analyzed with unpaired Student’s t test, one- or two-way analyses of variance with Bonferroni’s multiple comparison post hoc test, as appropriate. Dose–response curves were generated using nonlinear regression analyses. All analyses were performed with the GraphPad-Prism 7 software. A two-tailed \( P < 0.05 \) was considered significant.

Results

To confirm that CXCR4 and ACKR3 are expressed in hPPAEC and to assess whether both receptors form heteromeric complexes, we performed PLA to detect individual receptors and receptor-receptor interactions at single molecule resolution. As shown in Fig 1A, we observed positive PLA signals for both receptors individually and for CXCR4:ACKR3 heteromeric complexes. We then tested the effects of a panel of CXCR4 and ACKR3 ligands on hPPAEC monolayer permeability in transwell-permeability assays with FITC-dextran (Fig 1B). Ubiquitin, a non-cognate CXCR4 agonist that does not bind to ACKR3, CXCL11, an ACKR3 and CXCR3 agonist, TC14012, a synthetic CXCR4 antagonist and ACKR3 agonist, and AMD3100, a CXCR4 antagonist and allosteric ACKR3 agonist, did not affect hPPAEC permeability [26, 38–41]. In contrast, CXCL12 enhanced hPPAEC barrier function.

To be able to assess the effects of CXCL12 on thrombin-induced impairment of hPPAEC barrier function under optimized conditions, we determined the dose-response characteristics for thrombin in the permeability assay. The effects of thrombin (10–100 nM) on hPPAEC monolayer permeability are shown in Fig 2A. Thrombin dose- and time-dependently induced permeability of the hPPAEC monolayer. The time to reach plateau for the permeability-
inducing effects of thrombin increased with increasing thrombin concentrations (20 nM–55 min; 30 nM–75 min; 40 nM–135 min; 50 nM–255 min). Based on the results from Fig 2A, we analyzed the dose-effect relationship for thrombin-induced impairment of lung vascular endothelial cell barrier function at 55 min, 135 min and 255 min (Fig 2B). The thrombin-mediated effects showed a sigmoidal dose-effect relationship at all time points. The EC_{50} for thrombin-induced impairment of hPPAEC barrier function was 30 ± 2 nM after 55 min, 33 ± 2 nM after 135 min and 36 ± 2 nM after 255 min. The maximal impairment of endothelial barrier function (100% permeability = measured permeability in the absence of hPPAEC) reached 49 ± 3% at 55 min and 59 ± 4% and 72 ± 4% at 135 min and 255 min, respectively.

We then tested whether pre-treatment with CXCL12 and ubiquitin influences hyper-permeability of hPPAEC induced by a sub-maximal dose of thrombin. hPPAEC were treated for 10 min with either 100 nM of CXCL12 or ubiquitin, followed by the addition of thrombin (Fig 3A). Pre-treatment with both CXCR4 agonists significantly attenuated thrombin-induced hyper-permeability of hPPAEC. CXCL12 was more efficacious than ubiquitin in this assay. The effects of CXCL12 and ubiquitin when added after thrombin treatment of hPPAEC are shown in Fig 3B and 3C. CXCL12 significantly attenuated thrombin-induced permeability of hPPAEC and this effect could be antagonized with the CXCR4 antagonist AMD3100. AMD3100 treatment alone did not affect thrombin-mediated hyper-permeability of hPPAEC (Fig 3B). In contrast to CXCL12, ubiquitin-treatment and ubiquitin plus AMD3100-treatment did not modulate thrombin-induced hyper-permeability when tested in parallel experiments (Fig 3C). To exclude that the dose-effect relationship for ubiquitin is different from the dose-effect relationship for CXCL12, we tested ubiquitin in various concentrations (30 nM–3 μM), including concentrations above the K_{D}-value of ubiquitin for CXCR4 binding [39]. Ubiquitin treatment,
however, did not attenuate thrombin-induced hyper-permeability of the hPPAEC monolayer at any tested concentration under these experimental conditions (Fig 3D).

As observed in hPPAEC, thrombin also dose- and time-dependently induced permeability in the human lung microvascular endothelial cell line HULEC-5a (Fig 4A and 4B). When compared with hPPAEC, potency and efficacy of thrombin to induce permeability were reduced in

Fig 3. Effects of CXCL12 and ubiquitin on thrombin-induced impairment of hPPAEC monolayer permeability. hPPAEC were grown to a confluent monolayer on collagen-coated permeable membranes. (A) hPPAEC were pre-treated with vehicle, 100 nM of CXCL12 or ubiquitin for 10 minutes, as indicated, and then exposed to thrombin (50 nM), followed by the addition of FITC-dextran. Vehicle: no thrombin. Endothelial permeability was assessed by measuring the amount of FITC-dextran that permeated through the cell monolayer. No cells: 100% permeability (open circles). RFU: Relative fluorescence units. N = 3 in quadruplicate. *: p<0.05 vs. vehicle/thrombin. (B-D) hPPAEC were exposed to 35 nM of thrombin or vehicle. After 10 min, thrombin-exposed cells were treated with vehicle, CXCL12 (50 nM) and/or AMD3100 (10 μM) (B), with vehicle, ubiquitin (50 nM) and/or AMD3100 (10 μM) (C) or with various concentrations of ubiquitin (D) followed by the addition of FITC-dextran. The experimental conditions are indicated. Endothelial permeability was assessed by measuring the amount of FITC-dextran that permeated through the cell monolayer. RFU: Relative fluorescence units. N = 3 in quadruplicate. *: p<0.05 vs. thrombin/vehicle (2-way ANOVA/Bonferroni’s multiple comparison post hoc test).

https://doi.org/10.1371/journal.pone.0187949.g003
HULEC-5a. The EC$_{50}$ for thrombin-induced impairment of HULEC-5a barrier function was 64±7 nM after 55 min, 64±6 nM after 135 min and 57±5 nM after 255 min. Addition of CXCL12 and ubiquitin after treatment of HULEC-5a cells with a sub-maximal dose of...
thrombin significantly reduced thrombin-mediated impairment of endothelial cell barrier function (Fig 4C and 4D). The protective effects of both CXCR4 agonists on thrombin-induced permeability were comparable in HULEC-5a cells; CXCL12, however, was less efficacious in HULEC-5a cells than in hPPAEC.

Next, we utilized the Presto-Tango β-arrestin 2 recruitment assay to assess CXCR4 and ACKR3 agonist activities of the natural splice variants CXCL12α and CXCL12β, of truncated CXCL12 (3–68) and the engineered constitutively monomeric (CXCL121) and dimeric (CXCL122) CXCL12 variants. To confirm the dimeric and monomeric nature of the CXCL121 and CXCL122 variants, we performed polyacrylamide gel electrophoresis (PAGE) under non-reducing and reducing conditions (Fig 5). Consistent with the mono- and dimeric nature of the CXCL12 variants [27, 29], the migration position of CXCL122 was close to 20 kDa under non-reducing conditions, whereas CXCL12 and CXCL121 migrated to a position corresponding to a lower molecular mass. It should be noted that a faint band migrating at the position of CXCL122 was visible in non-reducing SDS-PAGE with CXCL12 (loaded at 4 μM), which is consistent with its dimerization Kd of 140 μM [42]. Under reducing conditions all three proteins showed an identical migration position, corresponding to the monomeric molecular mass of approximately 8 kDa.

In addition, we tested CXCL12 S-S4V, a protease resistant mutant, CXCL12 K27A/R41A/R47A, which shows significantly reduced heparan sulfate proteoglycan binding properties, and CXCL12 R47E, which activates CXCR4 with reduced potency, as compared with CXCL12α. The dose-response curves are shown in Fig 6 and Table 1 summarizes the corresponding EC50 concentrations and top plateau values (efficacy) for each protein.

All proteins except CXCL123–68, which lacked relevant CXCR4 activity, showed comparable efficacy to recruit β-arrestin 2 to CXCR4. There were no statistically significant differences between the EC50 concentrations for CXCL12α, CXCL12β, CXCL121 and CXCL122 in the CXCR4 Presto-Tango assay. The potencies of CXCL12 S-S4V, CXCL12 R47E and CXCL12 K27A/R41A/R47A were significantly lower than the potency of CXCL12α to recruit β-arrestin 2 to CXCR4.

In contrast, all proteins induced β-arrestin 2 recruitment to ACKR3 with an EC50 in the low nM range (p<0.05 for all vs. CXCL12α). While the efficacy for β-arrestin 2 recruitment to ACKR3 was significantly reduced for CXCL12 (3–68), the efficacies of all other proteins for β-arrestin 2 recruitment to ACKR3 were comparable.
Table 1. CXCR4 and ACK3 activity of CXCL12/CXCL12 variants—PRESTO-Tango.

|                   | CXCR4         |       | ACK3        |       |
|-------------------|---------------|-------|-------------|-------|
|                   | EC50 (nM)     | efficacy | EC50 (nM) | efficacy |
| CXCL12α           | 5.18±4.4      | 100    | 5.8±8.6     | 100   |
| CXCL12β           | 1.4±0.5       | 73±11  | 1.5±0.8     | 103±2 |
| CXCL121           | 27±11         | 103±10 | 5.6±2.1     | 98±8  |
| CXCL122           | 2.4±1.3       | 90±19  | 8.8±0.8     | 87±12 |
| CXCL12 S-S4V       | 7.5±30  (0.047) | 117±27 | 0.7±1.4     | 88±12 |
| CXCL12 R47E        | 127±52 (<0.01)| 105±18 | 0.4±0.02    | 86±7  |
| CXCL12 K27A R41A R47A | 145±95 (<0.01) | 111±17 | 1.2±1.6     | 83±7  |
| CXCL12 (3–68)     | >10³          | nd     | 13.3±13.5   | 19±2  (<0.01) |

Data are mean±SD. %. Relative efficacy in % of the efficacy of CXCL12α (wild type). N = 9 for CXCL12α, n = 3 for all other proteins. Data were compared with 1-way ANOVA/Bonferroni post hoc testing. Statistically significant differences vs. CXCL12α are shown in parenthesis. nd: not determined.

https://doi.org/10.1371/journal.pone.0187949.t001
Figs 7 and 8 show the effects of the proteins on thrombin-mediated impairment of hPPAEC barrier function when tested in concentrations between 0.05–50 nM in parallel experiments. CXCL12 (3–68) did not attenuate thrombin-induced impairment of hPPAEC barrier function. All other proteins inhibited thrombin-mediated impairment of hPPAEC barrier function with a similar time-dependency of their effects.

https://doi.org/10.1371/journal.pone.0187949.g007

Figs 7 and 8 show the effects of the proteins on thrombin-mediated impairment of hPPAEC barrier function when tested in concentrations between 0.05–50 nM in parallel experiments. CXCL12 (3–68) did not attenuate thrombin-induced impairment of hPPAEC barrier function. All other proteins inhibited thrombin-mediated impairment of hPPEAC barrier function with a similar time-dependency of their effects.
Fig 8. Dose-dependent effects of CXCL12α, CXCL12β, and CXCL12γ on thrombin-induced impairment of hPPAEC monolayer permeability. hPPAEC cells were grown to a confluent monolayer on collagen-coated permeable membranes. hPPAEC were then exposed to 35 nM of thrombin. After 10 min, thrombin-exposed cells were treated with vehicle or 50 nM (A), 5 nM (B), 0.5 nM (C) or 0.05 nM (D) of the various proteins, as indicated. In (D) 5 nM CXCL12α was used as a positive control. N = 3 in quadruplicate.

https://doi.org/10.1371/journal.pone.0187949.g008

Fig 9 shows the comparison of their end-point (t = 255 min) dose-response profiles. Except for CXCL12 (3–68), the efficacies of all other proteins to inhibit thrombin-induced impairment of hPPAEC barrier function were comparable. CXCL12α, CXCL12β, CXCL12γ and CXCL12 K27A/R41A/R47A showed similar potencies to inhibit thrombin-mediated hyper-permeability of hPPAEC with EC_{50} concentrations between 0.05–0.5 nM. The potencies of CXCL12 R47E and CXCL12 S-S4V were one order of magnitude lower (EC_{50} between 0.5–
CXCL12 affected thrombin-mediated hPPAEC barrier impairment only at a concentration of 50 nM.

Discussion

In the present study, we evaluated the effects of CXCR4 and ACKR3 ligands on the barrier function of human lung endothelial cells. CXCL12 has previously been described to enhance transendothelial electrical resistance, a surrogate marker of endothelial barrier function, of bovine aortic, human pulmonary artery and umbilical vein endothelial cells [22]. Furthermore, pre-treatment of bovine aortic endothelial cells with CXCL12 has been reported to attenuate thrombin-induced FITC-dextran transfer in transwell permeability assays. Likewise, co-treatment of human microvascular endothelial cells with CXCL12 or CTCE-0214, a synthetic CXCL12 analogue, plus thrombin attenuated the reduction of transendothelial resistance that was detectable with thrombin alone [15, 22]. Our observations from the present study are in
agreement with previous reports and now provide direct evidence that CXCL12 enhances barrier function of hPPAEC in the absence of permeability-inducing agents. In addition, we demonstrate that pre-treatment of hPPAEC with CXCL12 and with the non-cognate CXCR4 agonist ubiquitin, which does not bind to ACKR3 [38], attenuates thrombin-mediated hPPAEC barrier function impairment. These findings provide a possible mechanism underlying lung protective effects of intravenous CXCL12 pre-treatment in an oleate-induced lung injury model in rabbits and of ubiquitin pre-treatment in an endotoxic shock model in pigs [17, 20].

Although pre- and co-treatment experiments provide information on possible preventive properties of CXCR4 agonists, such experiments are unable to address therapeutic potential. Thus, we performed post-treatment experiments and detected that activation of CXCR4 after thrombin-exposure of hPPAEC and HULEC5a cells attenuates thrombin-mediated impairment of lung endothelial barrier function. These findings support the concept that CXCR4 agonists have therapeutic potential to limit thrombin-mediated pulmonary vascular leakage, which likely contributed to lung protective effects of CXCR4 agonists that have been observed in various models when administered after the insult [15, 17, 18, 21, 43].

In contrast to CXCL12, the non-cognate CXCR4 agonist ubiquitin did not enhance hPPAEC barrier function in the absence of thrombin. As compared with CXCL12, ubiquitin was less efficacious to reduce thrombin-mediated barrier function impairment in pre-treatment experiments with hPPAEC, showed similar efficacy to protect barrier function after thrombin exposure of HUELC5a and failed to protect barrier function after thrombin exposure of hPPAEC. These findings could be explained by ubiquitin’s lower affinity for and weaker agonist activity at CXCR4, as compared with CXCL12 [38, 39, 44–46].

Recently, we provided evidence that ubiquitin functions as a biased CXCR4 agonist, which does not recruit β-arrestin 2 to CXCR4 [47]. Thus, it appears also possible that the differences between CXCL12 and ubiquitin that we observed in the present study reflect differences in functional outcomes of balanced and biased CXCR4 signaling in lung endothelial cells.

Because none of the ACKR3 agonists affected hPPAEC barrier function and AMD3100 abolished protective effects of CXCL12 on thrombin-mediated barrier function impairment, activation of ACKR3 alone appears not to contribute to the observed effects.

Previously, CXCR4 has been shown to form heteromeric complexes with ACKR3 in expression systems and in human vascular smooth muscle cells [34–36, 48, 49]. Our present finding that PLA signals for CXCR4 and ACKR3 interactions are also detectable in hPPAEC suggests the existence of such endogenous receptor heteromers in the lung endothelium. Thus, another explanation for the observed differences between CXCL12 and ubiquitin that we observed in the present study reflect differences in functional outcomes of balanced and biased CXCR4 signaling in lung endothelial cells.

Among the CXCL12 variants that we tested, only CXCL12 (3–68) lacked relevant CXCR4 activity, showed significantly reduced efficacy to activate ACKR3 in Presto-Tango assays and did not attenuate thrombin-induced hPPAEC barrier function impairment. This loss of function is consistent with the loss of function of N-terminal truncated CXCL12 that has been reported previously in other assay systems [23–25].

As expected, both natural CXCL12 splice variants, CXCL12α and CXCL12α, showed comparable properties in Presto-Tango and permeability assays [26]. CXCL12 exists as a monomer at low concentrations and forms dimers at high concentrations or when bound to heparan sulfate on the endothelial surface [31, 50, 51]. Consistent with previous reports, the constitutive
monomeric CXCL12 variant (CXCL12₁) showed a behavior similar to wild type proteins in CXCR4/ACKR3 β-arrestin 2 recruitment assays and in permeability assays [27, 28]. Despite activities of the disulfide-locked dimeric CXCL12 variant CXCL12₂ in β-arrestin 2 recruitment assays for CXCR4 and ACKR3 that were comparable with CXCL12α/β, CXCL12₂ showed significantly reduced potency to attenuate thrombin-induced permeability of hPPEAC. The previous finding that CXCL12₂ binds to ACKR3 with very low affinity is not contradictory to our findings in ACKR3 β-arrestin 2 recruitment assays because maximal biological responses of other GPCRs have been observed at ligand occupancies of only a small fraction of receptors [28, 52, 53] and a large receptor reserve is likely in expression systems, such as the Presto-Tango assay. The effects of CXCL12₂ in CXCR4 β-arrestin 2 recruitment assays that we observed using the Presto-Tango cell system, however, are conflicting with previous measurements in intermolecular bioluminescence resonance energy transfer (BRET) assays [28]. The Presto-Tango assay utilizes a transcriptional read-out that is measured several hours after the actual signaling event. Thus, it appears possible that few β-arrestin recruitment events upon ligand binding, which may not generate a significant intermolecular BRET signal, can lead to transcription of luciferase in the Presto-Tango system. Furthermore, as compared to previous intermolecular BRET assays in which cells were exposed to CXCL12₂ for 30 min [28], cells were exposed to CXCL12₂ in our Presto-Tango assays for longer time periods, which may contribute to the observed effects. Irrespective of this discrepancy, the low potency of CXCL12₂ to inhibit thrombin-mediated barrier function impairment in the present study in combination with the previously described lack of chemotactic activity of CXCL12₂ [28, 29] demonstrate that this variant does not induce the complete spectrum of biological effects that are mediated via CXCR4 and/or ACKR3 upon activation with the wild type proteins and the constitutively monomeric variant.

In agreement with the low potency of CXCL12 R47E to activate Ca²⁺ signaling via CXCR4 [29], we observed that this mutant also induces β-arrestin 2 recruitment to CXCR4 and antagonizes thrombin-mediated hyperpermeability of hPPEAC with reduced potency, but retains ACKR3 activity comparable to wild type proteins. Similarly, the protease resistant mutant CXCL12 S-S4V showed reduced CXCR4 activity in Presto-Tango and permeability assays but retained ACKR3 activity. These findings are in agreement with previous effects of this mutant in CXCR4/ACKR3 β-arrestin recruitment and chemotaxis assays [30]. The observations that CXCL12 R47E and CXCL12 S-S4V showed reduced CXCR4 activity but retained ACKR3 activity further supports the assumption that protection from thrombin-mediated hPPEAC barrier impairment is mediated via CXCR4.

CXCL12 is known to bind to heparin oligosaccharides, which promotes dimerization, interferes with CXCL12 binding to CXCR4 and immobilizes CXCL12 on the endothelial surface to establish a concentration gradient required for cell trafficking [31, 54–56]. CXCL12 K27A/ R41A/R47A, which binds heparan sulfates with significantly reduced affinity [31], was the only mutant protein that inhibited thrombin-mediated impairment of hPPEAC barrier function with that same potency as wild type proteins and CXCL12₁. This mutant, however, showed the lowest potency to activate CXCR4 in β-arrestin 2 recruitment assays and retained high potency to activate ACKR3. These data suggest that the K27, R41 and R47 mutations reduced the binding affinity for CXCR4 or the efficacy to induce signaling events at lower concentrations. The high potency of this mutant to reduce thrombin-induced barrier function impairment, however, can be explained by its reduced heparan sulfate binding properties, which reduces the proportion of protein that is immobilized on the surface of hPPEAC and thus, is not available for receptor activation [57]. The latter suggests that CXCL12 binding to heparan sulfate on HTLA cells, which were used in Presto-Tango assays, does not significantly affect CXCR4 binding and signaling. This implies that distinct cell surface heparan sulfate...
proteoglycan expression patterns between various cell types modulate CXCL12-mediated biological functions.

In conclusion, our findings suggest CXCR4 as a possible drug target to attenuate thrombin-mediated impairment of lung endothelial barrier function, demonstrate that stimulation of human lung endothelial cells with cognate and non-cognate CXCR4 agonists results in functional differences and provide initial information on the structure-function relationship for CXCL12-mediated protection from thrombin-induced barrier function impairment in primary human lung endothelial cells. Our findings indicate that the protective effects of CXCL12 are dictated by its CXCR4 agonist activity and by interactions of distinct protein moieties with heparan sulfate proteoglycans on the endothelial cell surface. Interestingly, in disease conditions that are likely associated with thrombin-induced endothelial permeability impairment, such as sepsis or trauma, systemic CXCL12 concentrations have been reported to increase to levels within the range of the EC$_{50}$ for CXCL12 to attenuate thrombin-induced barrier function impairment in our permeability assays [58–60]. This may suggest that activation of CXCR4 by its endogenous agonists constitutes a protective mechanism to attenuate endothelial barrier function impairment by thrombin in disease conditions and implies that treatment with exogenous CXCR4 agonists augments this protective response. Our findings are expected to facilitate the development of engineered compounds with improved pharmacological properties to attenuate thrombin-induced vascular leakage in the pulmonary circulation, which may have the potential to attenuate development of lung injury and ARDS.

Supporting information

S1 Dataset. All data sets are provided in this file “S1 data sets.xlsx”.

Acknowledgments

This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Peer Reviewed Medical Research Program under Award No. W81XWH-15-1-0262 and by the National Institute of General Medical Sciences (Awards R01GM107495). The content is solely the responsibility of the authors. The authors declare that they have no conflict of interest.

Author Contributions

Conceptualization: Brian F. Volkman, Matthias Majetschak.

Formal analysis: You-Hong Cheng, Jonathan M. Eby, Matthias Majetschak.

Funding acquisition: Matthias Majetschak.

Investigation: You-Hong Cheng, Jonathan M. Eby.

Methodology: Heather M. LaPorte, Brian F. Volkman.

Project administration: Matthias Majetschak.

Supervision: Matthias Majetschak.

Writing – original draft: Matthias Majetschak.

Writing – review & editing: You-Hong Cheng, Jonathan M. Eby, Heather M. LaPorte, Brian F. Volkman, Matthias Majetschak.
References

1. Blank R, Napolitano LM. Epidemiology of ARDS and ALI. Crit Care Clin. 2011; 27(3):439–58. https://doi.org/10.1016/j.ccc.2011.05.005 PMID: 21742210.

2. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012; 307(23):2526–33. Epub 2012/07/17. https://doi.org/10.1001/jama.2012.5665 PMID: 22797452.

3. Gonzales JN, Lucas R, Verin AD. The Acute Respiratory Distress Syndrome: Mechanisms and Perspective Therapeutic Approaches. Austin J Vasc Med. 2015; 2(1). PMID: 26973981; PubMed Central PMCID: PMC4786180.

4. Dushianthan A, Grocott MP, Postle AD, Cusack R. Acute respiratory distress syndrome and acute lung injury. Postgrad Med J. 2011; 87(1031):612–22. https://doi.org/10.1136/pgmj.2011.118398 PMID: 21642654.

5. Ware LB. Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin Respir Crit Care Med. 2006; 27(4):337–49. Epub 2006/08/16. https://doi.org/10.1055/s-2006-948288 PMID: 16909368.

6. Johnson ER, Matthay MA. Acute lung injury: epidemiology, pathogenesis, and treatment. J Aerosol Med Pulm Drug Deliv. 2010; 23(4):243–52. https://doi.org/10.1089/jamp.2009.0775 PMID: 20073554; PubMed Central PMCID: PMC3133560.

7. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000; 407(6801):258–64. https://doi.org/10.1038/35025229 PMID: 11001069.

8. Alberelli MA, De Candia E. Functional role of protease activated receptors in vascular biology. Vasc Pharmacol. 2014; 62(2):72–81. https://doi.org/10.1016/j.vph.2014.06.001 PMID: 24924409.

9. Kawkitinarong K, Linz-McGillen L, Brukvo KG, Garcia JG. Differential regulation of human lung epithelial and endothelial barrier function by thrombin. Am J Respir Cell Mol Biol. 2004; 31(5):517–27. https://doi.org/10.1165/rcmb.2003-0432OC PMID: 15284075.

10. Mihara K, Ramachandran R, Saifeedde M, Hansen KK, Renaux B, Polley D, et al. Thrombin-Mediated Direct Activation of Protease-Activated Receptor-2: Another Target for Thrombin Signaling. Mol Pharmacol. 2016; 89(5):606–14. https://doi.org/10.1124/mol.115.102723 PMID: 26957205.

11. Gur-Cohen S, Kollet O, Graf C, Esmon CT, Ruf W, Lapidot T. Regulation of long-term repopulating hematopoietic stem cells by EPCR/PAR1 signaling. Ann N Y Acad Sci. 2016; 1370(1):65–81. https://doi.org/10.1111/nyas.13013 PMID: 26928241.

12. Arachiche A, Mumaw MM, de la Fuente M, Nieman MT. Protease-activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1-enhanced cleavage of PAR4 by alpha-thrombin. J Biol Chem. 2013; 288(45):32553–62. https://doi.org/10.1074/jbc.M113.472373 PMID: 24097976; PubMed Central PMCID: PMC3820888.

13. Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci U S A. 1999; 96(20):11023–7. PMID: 10500117; PubMed Central PMCID: PMC34235.

14. Zhang P, Gruber A, Kasuda S, Kimmelstiel C, O’Callaghan K, Cox DH, et al. Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 peptide. Circulation. 2012; 126(1):83–91. https://doi.org/10.1161/CIRCULATIONAHA.112.091918 PMID: 22705889; PubMed Central PMCID: PMC3423084.

15. Guo C, Goodwin AJ, Buie JN, Cook JA, Halushka PV, Argraves K, et al. A Stromal Cell-derived Factor 1 analogue improves Endothelial Cell Function in Lipopolysaccharide-induced Acute Respiratory Distress Syndrome. Mol Med. 2016. https://doi.org/10.2119/molmed.2015.00240 PMID: 27031787; PubMed Central PMCID: PMCPMC5004713 Medicine, or other interests that might be perceived to influence the results and discussion reported in this paper.

16. Garcia-Covarrubias L, Manning EW 3rd, Sorell LT, Pham SM, Majestschak M. Ubiquitin enhances the Th2 cytokine response and attenuates ischemia-reperfusion injury in the lung. Crit Care Med. 2008; 36(3):979–82. https://doi.org/10.1097/CCM.0b013e318164e417 PMID: 18209671.

17. Majestschak M, Cohn SM, Nelson JA, Burton EH, Ober tackle U, Proctor KG. Effects of exogenous ubiquitin in lethal endotoxemia. Surgery. 2004; 135(5):536–43. https://doi.org/10.1016/j.surg.2003.09.006 PMID: 1518591.

18. Earle SA, Proctor KG, Patel MB, Majestschak M. Ubiquitin reduces fluid shifts after traumatic brain injury. Surgery. 2005; 138(3):431–8. https://doi.org/10.1016/j.surg.2005.06.026 PMID: 16213895.

19. Baker TA, Romero J, Bach HH, Strom JA, Gamelli RL, Majestschak M. Effects of exogenous ubiquitin in a polytrauma model with blunt chest trauma. Crit Care Med. 2012. Epub 2012/05/25. https://doi.org/10.1097/CCM.0b013e3182514ed9 PMID: 22622399.
20. Guo W, Li Z, Xie X, Tan T, Wang S, Xie N, et al. Stromal cell-derived factor-1alpha attenuates oleate-induced acute lung injury in rabbits. Biochem Biophys Res Commun. 2014. https://doi.org/10.1016/j.bbrc.2014.07.033 PMID: 25099880.

21. Nassoiy SP, Babu FS, LaPorte HM, Majetschak M. Pharmacological modulation of C-X-C motif chemokine receptor 4 influences development of acute respiratory distress syndrome after lung ischemia-reperfusion injury. Clin Exp Pharmacol Physiol. 2017. https://doi.org/10.1111/1440-1681.12845 PMID: 28815665.

22. Kobayashi K, Sato K, Kida T, Omori K, Hori M, Ozaki H, et al. Stromal cell-derived factor-1alpha/C-X-C chemokine receptor type 4 axis promotes endothelial cell barrier integrity via phosphoinositide 3-kinase and Rac1 activation. Arterioscler Thromb Vasc Biol. 2014; 34(8):1716–22. https://doi.org/10.1161/ATVBAHA.114.303890 PMID: 24925969.

23. Crump MP, Gong JH, Loetscher P, Rajarathnam K, Amara A, Arentzana-Seisdedos F, et al. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. Embo J. 1997; 16(23):6996–7007. https://doi.org/10.1093/ emboj/16.23.6996 PMID: 9384579.

24. Janssens R, Mortier A, Boff D, Ruytinx P, Gouwy M, Vantilt B, et al. Truncation of CXCL12 by CD26 reduces its CXC chemokine receptor 4- and atypical chemokine receptor 3-dependent activity on endothelial cells and lymphocytes. Biochem Pharmacol. 2017; 132:92–101. https://doi.org/10.1016/j.bcp.2017.03.009 PMID: 28322746.

25. Proost P, Struyf S, Schois D, Durinx C, Wuys A, Lenaerts JP, et al. Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Lett. 1998; 432(1–2):73–6. PMID: 9710254.

26. Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, et al. International Union of Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 2014; 66(1):1–79. Epub 2013/11/13. https://doi.org/10.1124/pr.113.007724 PMID: 24218476; PubMed Central PMCID: PMC3880466.

27. Ziarek JJ, Kleist AB, London N, Raveh B, Montpas N, Bonneterre J, et al. Structural basis for chemokine recognition by a G protein-coupled receptor and implications for receptor activation. Sci Signal. 2017; 10(471). https://doi.org/10.1126/scisignal.aah5756 PMID: 28325822.

28. Druy L, Ziarek JJ, Gravel S, Veldkamp CT, Takekoshi T, Hwang ST, et al. Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways. Proc Natl Acad Sci U S A. 2011; 108(43):17655–60. Epub 2011/10/13. https://doi.org/10.1073/pnas.1101133108 PMID: 21990345; PubMed Central PMCID: PMC3203819.

29. Veldkamp CT, Seibert C, Peterson FC, De la Cruz NB, Haugner JC 3rd, Basnet H, et al. Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Sci Signal. 2008; 1(37):ra4. https://doi.org/10.1126/scisignal.1160755 PMID: 18799424.

30. Segers VF, Tokunou T, Higgins LJ, MacGillivray C, Gannon J, Lee RT. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation. 2007; 116(15):1683–92. https://doi.org/10.1161/CIRCULATIONAHA.107.178718 PMID: 17875967.

31. Ziarek JJ, Veldkamp CT, Zhang F, Murray NJ, Kartz GA, Liang X, et al. Heparin oloxisaccharides inhibit chemokine (CXC motif) ligand 12 (CXCL12) cardioprotection by binding orthogonal to the dimerization interface, promoting oligomerization, and competing with the chemokine (CXC motif) receptor 4 (CXCR4) N terminus. J Biol Chem. 2013; 288(1):737–46. https://doi.org/10.1074/jbc.M112.394064 PMID: 23148226; PubMed Central PMCID: PMC3537072.

32. Veldkamp CT, Kopilinski CA, Jensen DR, Peterson FC, Smits KM, Smith BL, et al. Production of Recombinant Chemokines and Validation of Refolding. Methods Enzymol. 2016; 570:539–65. https://doi.org/10.1016/bs.mie.2015.09.031 PMID: 26921961; PubMed Central PMCID: PMCPMC4811038.

33. Kroese WK, Sassano MF, Huang XP, Lansu K, McCorry JD, Giguetre PM, et al. PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome. Nat Struct Mol Biol. 2015; 22(5):362–9. https://doi.org/10.1038/nsmb.3014 PMID: 25895059; PubMed Central PMCID: PMCPMC4424118.

34. Evans AE, Tripathi A, Laporte HM, Brueggemann LI, Singh AK, Albee LJ, et al. New insights into mechanisms and functions of chemokine (C-X-C motif) receptor 4 heteromerization in vascular smooth muscle. J Mol Sci. 2016 Jun 20; 17(5). pii: E971. https://doi.org/10.3390/jm17060971 PMID: 27331810; PubMed Central PMCID: PMC4926503.

35. Tripathi A, Vana PG, Chavan TS, Brueggemann LI, Byron KL, Tarasova NI, et al. Heteromerization of chemokine (C-X-C motif) receptor 4 with alpha1A/B-adrenergic receptors controls alpha1-adrenergic receptor function. Proc Natl Acad Sci U S A. 2015; 112(19):E1669–E76. https://doi.org/10.1073/pnas.1417564112 PMID: 25775528; PubMed Central PMCID: PMC4386352.
36. Albee LJ, Eby JM, Tripathi A, Laporte HM, Gao X, Volkman BF, et al. α1-Adrenoceptors function within hetero-oligomeric complexes with chemokine receptors ACKR3 and CXCR4 in vascular smooth muscle cells. J Am Heart Assoc. 2017 Aug 17; 6(8). pii: e006575. https://doi.org/10.1161/JAHA.117.006575 PMID: 28682946; PubMed Central PMCID: PMC5586474.

37. Tripathi A, Gaponenko V, Majetschak M. Commercially available antibodies directed against alpha-adrenergic receptor subtypes and other G protein-coupled receptors with acceptable selectivity in flow cytometry experiments. Naunyn Schmiedebergs Arch Pharmacol. 2015. https://doi.org/10.1007/s00210-015-1196-0 PMID: 26660071; PubMed Central PMCID: PMC4718873.

38. Saini V, Staren DM, Ziarek JJ, Nashaat ZN, Campbell EM, Volkman BF, et al. The CXC chemokine receptor 4 ligands ubiquitin and stromal cell-derived factor-1alpha function through distinct receptor interactions. J Biol Chem. 2011; 286(38):33466–77. https://doi.org/10.1074/jbc.M111.233742 PMID: 21757744; PubMed Central PMCID: PMC3190899.

39. Saini V, Marchese A, Majetschak M. CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin. J Biol Chem. 2010; 285(20):15566–76. https://doi.org/10.1074/jbc.M110.103406 PMID: 20228059; PubMed Central PMCID:PMC2865327.

40. Gravel S, Malouf C, Boulaïs PE, Berchiche YA, Oishi S, Fuji N, et al. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains. J Biol Chem. 2010; 285(49):39393–43. Epub 2010/10/20. https://doi.org/10.1074/jbc.C110.147470 PMID: 20956518; PubMed Central PMCID: PMC2992227.

41. Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmacol. 2009; 75(5):1240–7. Epub 2009/03/04. https://doi.org/10.1124/mol.108.053389 PMID: 19255243.

42. Ziarek JJ, Getschman AE, Butler SJ, Taleski D, Stephens B, Kufareva I, et al. Sulfopeptide probes of the CXCR4/CXCL12 interface reveal oligomer-specific contacts and chemokine allosterism. ACS Chem Biol. 2013; 8(9):1955–63. https://doi.org/10.1021/cb400274f PMID: 23802178; PubMed Central PMCID: PMCPMC3783652.

43. Baker TA, Romero J, Bach HH, Strom JA, Gamelli RL, Majetschak M. Effects of exogenous ubiquitin in a polytrauma model with blunt chest trauma. Crit Care Med. 2012; 40(8):2376–84. https://doi.org/10.1097/CCM.0b013e3182514ed9 PMID: 22622399; PubMed Central PMCID: PMC3886622.

44. Saini V, Marchese A, Tang WJ, Majetschak M. Structural determinants of ubiquitin-CXC chemokine receptor 4 interaction. J Biol Chem. 2011; 286(51):44145–52. https://doi.org/10.1074/jbc.M111.288505 PMID: 22039044; PubMed Central PMCID: PMC3243501.

45. Saini V, Romero J, Marchese A, Majetschak M. Ubiquitin receptor binding and signaling in primary human leukocytes. Commun Integr Biol. 2010; 3(6):608–10. https://doi.org/10.4161/cib.3.6.13375 PMID: 21331255; PubMed Central PMCID:PMC3038079.

46. Tripathi A, Saini V, Marchese A, Volkman BF, Tang WJ, Majetschak M. Modulation of the CXC chemokine receptor 4 agonist activity of ubiquitin through C-terminal protein modification. Biochemistry. 2013; 52(24):4184–92. https://doi.org/10.1021/bi400254f PMID: 23697661; PubMed Central PMCID: PMCPMC3783652.

47. Eby JM, Abdelkarim H, Albee LJ, Tripathi A, Gao X, Volkman BF, et al. Functional and structural consequences of chemokine (C-X-C motif) receptor 4 activation with cognate and non-cognate agonists. Mol Cell Biochem. 2017; 1–9. https://doi.org/10.1007/s10589-017-2989-0 PMID: 28455789.

48. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood. 2009; 113(24):6085–93. Epub 2009/04/22. https://doi.org/10.1182/blood-2008-12-196618 PMID: 19380869.

49. Decaillot FM, Kazmi MA, Lin Y, Ray-Saha S, Sakmar TP, Sachdev P. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. J Biol Chem. 2011; 286(37):32188–97. Epub 2011/07/07. https://doi.org/10.1074/jbc.M111.277038 PMID: 21730065; PubMed Central PMCID: PMC3173186.

50. Veldkamp CT, Peterson FC, Pelzeck AJ, Volkman BF. The monomer-dimer equilibrium of stromal cell-derived factor-1 (CXCL12) is altered by pH, phosphate, sulfate, and heparin. Protein Sci. 2005; 14(4):1071–81. Epub 2005/03/03. https://doi.org/10.1100/p.041219505 PMID: 15741341; PubMed Central PMCID: PMC2253449.

51. Murphy JW, Cho Y, Sachpatzidis A, Fan C, Hodsdon ME, Lolis E. Structural and functional basis of CXCL12 (stromal cell-derived factor-1 alpha) binding to heparin. J Biol Chem. 2007; 282(13):10018–27. https://doi.org/10.1074/jbc.M608796200 PMID: 17264079; PubMed Central PMCID: PMCPMC3684283.

52. Gifford AN, Bruneus M, Gatley SJ, Lan R, Makriyannis A, Volkov ND. Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther. 1999; 288(2):478–83. Epub 1999/01/26. PMID: 9918548.
53. Ethier MF, Schaefer OP, Samant N, Yamaguchi H, Madison JM. Muscarinic receptor reserve for inhibition of cAMP accumulation in bovine trachealis cells. Am J Physiol. 1996; 270(2 Pt 1):L199–207. Epub 1996/02/01. PMID: 8779988.

54. Handel TM, Johnson Z, Crown SE, Lau EK, Proudfoot AE. Regulation of protein function by glycosaminoglycans—as exemplified by chemokines. Annu Rev Biochem. 2005; 74:385–410. https://doi.org/10.1146/annurev.biochem.72.121801.161747 PMID: 15952892.

55. Johnson Z, Proudfoot AE, Handel TM. Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev. 2005; 16(6):625–36. https://doi.org/10.1016/j.cytogfr.2005.04.006 PMID: 15990353.

56. Sadir R, Baleux F, Grosdidier A, Imbert A, Lortat-Jacob H. Characterization of the stromal cell-derived factor-1alpha-heparin complex. J Biol Chem. 2001; 276(11):8288–96. https://doi.org/10.1074/jbc.M008112020 PMID: 11087743.

57. Verkaar F, van Offenbeek J, van der Lee MMC, van Lith L, Watts AO, Rops A, et al. Chemokine cooperativity is caused by competitive glycosaminoglycan binding. J Immunol. 2014; 192(8):3908–14. https://doi.org/10.4049/jimmunol.1302159 PMID: 24639348; PubMed Central PMCID: PMCPMC4198333.

58. Majetschak M. Extracellular ubiquitin: immune modulator and endogenous opponent of damage-associated molecular pattern molecules. J Leukoc Biol. 2011; 89(2):205–19. https://doi.org/10.1189/jlb.0510316 PMID: 20689098.

59. Franchini S, Marciano T, Sorlini C, Campochiaro C, Tresoldi M, Sabbadini MG, et al. Serum CXCL12 levels on hospital admission predict mortality in patients with severe sepsis/septic shock. Am J Emerg Med. 2015; 33(12):1802–4. https://doi.org/10.1016/j.ajem.2015.08.047 PMID: 26387470.

60. Chen TJ, Wu WQ, Ying GR, Fu QY, Xiong K. Serum CXCL12 concentration in patients with severe traumatic brain injury are associated with mortality. Clin Chim Acta. 2016; 454:6–9. https://doi.org/10.1016/j.cca.2015.12.033 PMID: 26724366.